A long-acting tumor necrosis factor α-binding protein demonstrates activity in both in vitro and in vivo models of endometriosis

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 2, 2010, Pages 460-466

  Altan, Z Melis ^a   Denis, Deborah ^a   Kagan, David ^a,b   Grund, Eric M ^a,c   Palmer, Stephen S ^a   Nataraja, Selvaraj G ^a  

^a EMD SERONO INC   (United States)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c Escoublac   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 6; INTERLEUKIN 8; ITURELIX; MONOCYTE CHEMOTACTIC PROTEIN 1; TNF SOLUBLE HIGH AFFINITY RECEPTOR COMPLEX; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ENDOMETRIOSIS; ENDOMETRIUM CELL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; CELL LINE; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; ENDOMETRIOSIS; ENDOMETRIUM; FEMALE; GLYCOPROTEIN HORMONES, ALPHA SUBUNIT; HUMANS; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954892635     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.166488     Document Type: Article

References (36)

1. Akoum A, Lemay A, Brunet C, and Hébert J (1995) Secretion of monocyte chemotactic protein-1 by cytokine-stimulated endometrial cells of women with endometriosis. Le groupe d'investigation en gynecologie. Fertil Steril 63:322-328.
2. Akoum A, Lemay A, McColl S, Turcot-Lemay L, and Maheux R (1996) Elevated concentration and biologic activity of monocyte chemotactic protein-1 in the peritoneal fluid of patients with endometriosis. Fertil Steril 66:17-23. (Pubitemid 26190015)
3. Barrier BF, Bates GW, Leland MM, Leach DA, Robinson RD, and Propst AM (2004) Efficacy of anti-tumor necrosis factor therapy in the treatment of spontaneous endometriosis in baboons. Fertil Steril 81 (Suppl 1):775-779.
4. Becker CM, Wright RD, Satchi-Fainaro R, Funakoshi T, Folkman J, Kung AL, and D'Amato RJ (2006) A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. Am J Pathol 168:2074-2084.
5. Braundmeier AG and Nowak RA (2006) Cytokines regulate matrix metalloproteinases in human uterine endometrial fibroblast cells through a mechanism that does not involve increases in extracellular matrix metalloproteinase inducer. Am J Reprod Immunol 56:201-214.
6. Bruner-Tran KL, Eisenberg E, Yeaman GR, Anderson TA, McBean J, and Osteen KG (2002) Steroid and cytokine regulation of matrix metalloproteinase expression in endometriosis and the establishment of experimental endometriosis in nude mice. J Clin Endocrinol Metab 87:4782-4791.
7. Crosignani P, Olive D, Bergqvist A, and Luciano A (2006) Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update 12:179-189.
8. D'Antonio M, Martelli F, Peano S, Papoian R, and Borrelli F (2000) Ability of recombinant human TNF binding protein-1 (r-hTBP-1) to inhibit the development of experimentally-induced endometriosis in rats. J Reprod Immunol 48:81-98.
9. D'Hooghe TM, Nugent NP, Cuneo S, Chai DC, Deer F, Debrock S, Kyama CM, Mihalyi A, and Mwenda JM (2006) Recombinant human TNFRSF1A (r-hTBP1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. Biol Reprod 74:131-136.
10. Fedele L, Somigliana E, Frontino G, Benaglia L, and Vigano P (2008) New drugs in development for the treatment of endometriosis. Expert Opin Investig Drugs 17:1187-1202.
11. Galandrini R, Porpora MG, Stoppacciaro A, Micucci F, Capuano C, Tassi I, Di Felice A, Benedetti-Panici P, and Santoni A (2008) Increased frequency of human leukocyte antigen-E inhibitory receptor CD94/NKG2A-expressing peritoneal natural killer cells in patients with endometriosis. Fertil Steril 89:1490-1496.
12. Gazvani R and Templeton A (2002) Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. Reproduction 123:217-226. (Pubitemid 34144671)
13. Giudice LC and Kao LC (2004) Endometriosis. Lancet 364:1789-1799.
14. Grund EM, Kagan D, Tran CA, Zeitvogel A, Starzinski-Powitz A, Nataraja S, and Palmer SS (2008) Tumor necrosis factor-alpha regulates inflammatory and mesenchymal responses via mitogen-activated protein kinase kinase, p38, and nuclear factor kappaB in human endometriotic epithelial cells. Mol Pharmacol 73:1394-1404.
15. Harada T, Enatsu A, Mitsunari M, Nagano Y, Ito M, Tsudo T, Taniguchi F, Iwabe T, Tanikawa M, and Terakawa N (1999) Role of cytokines in progression of endometriosis. Gynecol Obstet Invest 47 (Suppl 1):34-39.
16. Hatam L, Schuval S, and Bonagura VR (1994) Flow cytometric analysis of natural killer cell function as a clinical assay. Cytometry 16:59-68. (Pubitemid 2068881)
17. Hirata T, Osuga Y, Yoshino O, Hirota Y, Harada M, Takemura Y, Morimoto C, Koga K, Yano T, Tsutsumi O, et al. (2005) Development of an experimental model of endometriosis using mice that ubiquitously express green fluorescent protein. Hum Reprod 20:2092-2096.
18. Koninckx PR, Craessaerts M, Timmerman D, Cornillie F, and Kennedy S (2008) Anti-TNF-alpha treatment for deep endometriosis-associated pain: a randomized placebo-controlled trial. Hum Reprod 23:2017-2023.
19. Lebovic DI, Mueller MD, and Taylor RN (2001) Immunobiology of endometriosis. Fertil Steril 75:1-10.
20. Lebovic DI, Mwenda JM, Chai DC, Mueller MD, Santi A, Fisseha S, and D'Hooghe T (2007) PPAR-gamma receptor ligand induces regression of endometrial explants in baboons: a prospective, randomized, placebo- and drug-controlled study. Fertil Steril 88:1108-1119.
21. Licastro F, Chiappelli M, Ianni M, and Porcellini E (2009) Tumor necrosis factoralpha antagonists: differential clinical effects by different biotechnological molecules. Int J Immunopathol Pharmacol 22:567-572.
22. Matsuzaki S, Canis M, Darcha C, Dallel R, Okamura K, and Mage G (2004) Cyclooxygenase-2 selective inhibitor prevents implantation of eutopic endometrium to ectopic sites in rats. Fertil Steril 82:1609-1615.
23. McKenna SD, Feger G, Kelton C, Yang M, Ardissone V, Cirillo R, Vitte PA, Jiang X, and Campbell RK (2007) Tumor necrosis factor (TNF)-soluble high-affinity receptor complex as a TNF antagonist. J Pharmacol Exp Ther 322:822-828.
24. Oosterlynck DJ, Cornillie FJ, Waer M, Vandeputte M, and Koninckx PR (1991) Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium. Fertil Steril 56:45-51.
25. Ozkan S, Murk W, and Arici A (2008) Endometriosis and infertility: epidemiology and evidence-based treatments. Ann N Y Acad Sci 1127:92-100.
26. Quaranta MG, Porpora MG, Mattioli B, Giordani L, Libri I, Ingelido AM, Cerenzia P, Di Felice A, Abballe A, De Felip E, et al. (2006) Impaired NK-cell-mediated cytotoxic activity and cytokine production in patients with endometriosis: a possible role for PCBs and DDE. Life Sci 79:491-498.
27. Sampson J (1927) Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. Am J Obstet Gynecol 14:422-469.
28. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, and Wagner C (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418-426.
29. Seli E and Arici A (2003) Endometriosis: interaction of immune and endocrine systems. Semin Reprod Med 21:135-144. (Pubitemid 36875689)
30. Seli E, Berkkanoglu M, and Arici A (2003) Pathogenesis of endometriosis. Obstet Gynecol Clin North Am 30:41-61.
31. Sidell N, Han SW, and Parthasarathy S (2002) Regulation and modulation of abnormal immune responses in endometriosis. Ann N Y Acad Sci 955:159-173. (Pubitemid 34271074)
32. Story L and Kennedy S (2004) Animal studies in endometriosis: a review. ILAR J 45:132-138.
33. Tanaka E, Sendo F, Kawagoe S, and Hiroi M (1992) Decreased natural killer cell activity in women with endometriosis. Gynecol Obstet Invest 34:27-30.
34. Umesaki N, Tanaka T, Miyama M, Mizuno K, Kawamura N, and Ogita S (1999) Increased natural killer cell activities in patients treated with gonadotropin releasing hormone agonist. Gynecol Obstet Invest 48:66-68.
35. Wilson TJ, Hertzog PJ, Angus D, Munnery L, Wood EC, and Kola I (1994) Decreased natural killer cell activity in endometriosis patients: relationship to disease pathogenesis. Fertil Steril 62:1086-1088.
36. Zeitvogel A, Baumann R, and Starzinski-Powitz A (2001) Identification of an invasive, N-cadherin-expressing epithelial cell type in endometriosis using a new cell culture model. Am J Pathol 159:1839-1852.